Health Canada has approved AbbVie’s (NYSE:ABBV) antibody-drug conjugate Elahere (mirvetuximab soravtansine) for ovarian cancer.
The treatment is approved for women who have received one to three other therapies.
More specifically, Elahere is approved for folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Elahere was given priority review and its approval was supported by data from the MIRASOL phase 3 trial.
It is given every three weeks as an intravenous infusion.
